Effect of inhaled Cromolyn on cough of mild persistent asthma in resistant patients to inhaled Corticosteroid and antileukotriene, A double blind randomized clinical trial.

Protocol summary

Summary
Objectives: The objective of this study is to determine the effect of cromolyn to standard therapy in mild persistent resistant to corticosteroid and anti leukotriene Asthma with normal Spirometry. Design: Prospective randomized controlled clinical trial (active comparator study). Setting and conduct: A pulmonary subspecialty clinic. Participants including major eligibility criteria: Sixty two asthmatic subjects with mild persistent corticosteroid and anti leukotriene resistant Asthma. Subjects suffering from other underlying diseases such as respiratory infection, sever or moderate Asthma, Rhinosinositis, Gastro-Oesophageal Reflux, other obstructive lung disease, vocal cord dysfunction, and reactive airway dysfunction syndrome will be excluded from study. After randomization eligible subjects will receive cromolyn or placebo. Independent pharmacists dispensed either Cromolyn or Placebo according to a computer generated randomization list. Intervention: Each cromolyn or placebo will be consumed for forty days, correct usage of spray and spacer will be educated to patients. After this period they will be evaluated for main parameters. Main outcome (variables) includes: change of clinical finding, change of Spirometry, change of Sputum cytology include inflammatory cell, change of ACT (Asthma control test) Questionnaire and change of FENO (Fractional Exhaled Nitric Oxide). These parameters will be evaluated again after completing the course of treatment.

General information

Acronym
IRCT registration information
IRCT registration number: IRCT201108042695N3
Registration date: 2014-04-13, 1393/01/24
Registration timing: retrospective

Last update:
Update count: 0
Registration date
2014-04-13, 1393/01/24

Scientific title
Effect of inhaled Cromolyn on cough of mild persistent asthma in resistant patients to inhaled Corticosteroid and antileukotriene, A double blind randomized clinical trial.

Public title
Effect of inhaled Cromolyn on persistent asthma

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria: cough with an intermittent course and history of airway hyper responsiveness; FEV1(Forced Expiratory volume in 1 second) more than 80% (mild asthma); No beneficial effect of inhaled Corticosteroid anti leukotriene during previous treatment. Exclusion criteria: Moderate or severe asthma; FEV1 (Forced Expiratory volume in 1 second) lees than 80%; Asthma
with wheezing; Respiratory infection; Treatment with systemic Corticosteroid; Other Obstructive lung disease; Rhinosinositis; Gastro-esophageal Reflux; Vocal Cord Dysfunction; Reactive airway dysfunction syndrome.

Age
No age limit
Gender
Both
Phase
2
Groups that have been masked
None
Sample size
Target sample size: 62
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features
Due to spontaneous remission of asthma and long term period of treatment with cromolyn double blind randomized clinical trial was used as the best method of study. All recruited asthmatic subjects will randomly divided to two groups of cromolyn inhaler and placebo by computer generated randomization list. One group will be treated by cromolyn or and other group will be received placebo for forty days. Both of them will use spray and the dosage will be 2 puff four times. The physician and pharmacist are blind to the exact drug which the subject will be started with. The cromolyn and placebo form is spray and identical in appearance. They have consecutively numbered for each patient according to the randomization schedule which is not introduced to the physician and pharmacist.

Secondary Ids
empty

Ethics committees

1
Ethics committee
Name of ethics committee
Mashhad branchbranch-Islamic Azad University-
Ethical committee- Department of research
Street address
Shahin Far Building- Sarab Street- Azadi street
City
Mashhad
Postal code
9178673799
Approval date
2011-04-24, 1390/02/04
Ethics committee reference number
A56-21

Health conditions studied

1
Description of health condition studied
Asthma
ICD-10 code
J45.32
ICD-10 code description
Mild Persistent Asthma, Status asthmaticus

Primary outcomes

1
Description
Chenge of FENO (Fractional Exhaled Nitric Oxide)
Timepoint
Before treatment and 40 days after treatment
Method of measurement

2
Description
Chenge of FEV1 (Forced Expiratory volume in 1 second)
Timepoint
Before treatment and 40 days after treatment
Method of measurement

3
Description
Chenge of Sputum Cytology
Timepoint
Before treatment and 40 days after treatment
Method of measurement
Sputum Cytology for frequency of inflammatory cell (Eosinophil, Neutrophil, Macrophage and Lymphocyte) defined by percentage calculated into 200 cell in each high power field Microscopic in magnification 40x in Sputum.

Secondary outcomes

1
Description
Chenge of IL-8
Timepoint
One year later
Method of measurement
Enzyme-linked immunosorbent assay (ELISA)
3

Description
Chenge of INF- GAMMA

Timepoint
One year later

Method of measurement
Enzyme-linked immunosorbent assay (ELISA)

3

Description
Chenge of IL-17

Timepoint
One year later

Method of measurement
Enzyme-linked immunosorbent assay (ELISA)

4

Description
Chenge of TLR-2

Timepoint
One year later

Method of measurement
Enzyme-linked immunosorbent assay (ELISA)

Intervention groups

1

Description
Steps before starting the study: Asthmatic subjects referred with cough and history of recurrence with or without reactive airway hyper responsiveness and without wheezing will be treated with one puff spray fluticasone 250 twice a day with spacer. Spacer usage will be educated. If they do not improve after one week oral Montelukast will be added to previous drug. Afterward chest x ray will be taken, if they do not improve again. In case of infiltration in favor of infection, they will cure with Doxycycline 100 mg or clarithromycin 500 mg two twice a day for 10 days. In subjects with normal chest X ray anti reflux therapy will be added to previous drugs including Fluticasone and montelukast. Patients whom do not improve with these regimens will be entered to our study. Phase one: Recruitment of subjects: Informed consent will be given after oral discussion. Parameters which will be evaluated before intervention include clinical physical exam and paraclinical evaluations such as Spirometry (with Spirometry super Spiro, Micro medical company, England), FENO (Chemilumine scence instrument, No Breath, Bed font company, England), Sputum Cytology for frequency of inflamatory cell (Eosinophile, Neutrophile, Macrophage and Lymphocyte) defined by percentage calculated into 200 cell in each high power field Microscopic in magnification 40x in Sputum and ACT (Validated Asthma control test Questionnaire). Some of the sputum will be freezed for secondary parameters evaluation including Toll like receptor 2, IL-8, IL-17 and INF-Gamma. These parameters will be evaluated by enzyme-linked immunosorbent assay (ELISA) method.

Category
Diagnosis

2

Description
After pretest evaluations, patients will be randomly divided in two groups and will be received cromolyn spray or placebo for 40 days four time daily two puff with spacer. Cromolyn and placebo have similar shape and have provided from Sina Daru company in Tehran, Iran by manager of study. Subjects will be educated for drug usage with spacer and mode of administration. Patients will follow for 10 days for exacerbation of Asthma which may be occured in subjects whom will receive placebo. After 40 days post test study will be performed. In this step subjects will be evaluated again for clinical exam and paraclinical parameters including Spirometry, FENO, Sputum Cytology and ACT Questionnaire. Some of the sputum will be freezed for secondary parameters evaluation including Toll like receptor 2, IL-8, IL-17 and INF-Gamma.

Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Mashhad branch-Islamic Azad University

Full name of responsible person
Mojtaba Meshkat

Street address
Shahin Far buildind, Sarab Street, Azadi avenue

City
Mashhad

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Mashhad Branch-Islamic Azad University

Full name of responsible person
Mojtaba Meshkat

Street address
Shahin Far building, Sarab street, Azadi Avenue

City
Mashhad

Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Mashhad Branch-Islamic Azad University

Proportion provided by this source
100

Public or private sector
Person responsible for general inquiries

Contact
Name of organization / entity
Mashhad Branch-Islamic Azad University
Full name of responsible person
Majid Mirsadraee
Position
Associate Professor
Other areas of specialty/work
Street address
No 80, 15th Kosar, Kosar Ave., Vakilabad Blv.
City
Mashhad
Postal code
91786
Phone
+98 51 1841 6694
Fax
+98 51 1881 6569
Email
majdjmirsadraee@mshdiau.ac.ir
Web page address
www.mshdiau.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Mashhad Branch-Islamic Azad University
Full name of responsible person
Majid Mirsadraee
Position
Associate Professor
Other areas of specialty/work
Street address
No 80, 15th Kosar, Kosar Ave., Vakilabad Blv.
City
Mashhad
Postal code
91786
Phone
+98 51 1841 6694
Fax
+98 51 1881 6569
Email
majdjmirsadraee@mshdiau.ac.ir
Web page address
www.mshdiau.ac.ir

Sharing plan
Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty